Hematology

Myelodysplastic Syndromes   

Questions discussed in this category


Are there particular mutations (eg SF3B1) or syndromes (eg MDS/MPN overlaps such as MDS/MPN-RS-T) where you are more apt to using lenalidomide?

Can results from emerging AML data be extrapolated to high risk MDS populations? Is there data to guide the choice of continuing the HMA in combinati...

Given the rarity of this in MF, is it still predictive of response to lenalidomide therapy?


Papers discussed in this category


The Lancet. Oncology, 2009-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-05-15

Cancer, 2011-06-15

American journal of hematology, 2009-09

Cancer, 2010-08-15

The New England journal of medicine, 2016-11-24

The Lancet. Haematology, 2018-01

Therapeutic advances in hematology, 2012-04

J Clin Oncol, 2021 Jan 13